Home/Pipeline/ERRα Program

ERRα Program

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Lead Pharma

About Lead Pharma

Lead Pharma is a private, clinical-stage biotech leveraging a robust, integrated discovery engine to develop small-molecule drugs for oncology and immunology. The company has a proven track record of advancing programs to clinical stages, evidenced by its partnered RORγt inhibitor (SAR441169 with Sanofi) and an internal ERRα program. With a focus on difficult-to-drug targets, Lead Pharma's business model centers on internal pipeline development and strategic partnerships to bring life-changing treatments to patients.

View full company profile

Therapeutic Areas

Autoimmune Diseases Cancer

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active